12:00 AM
Sep 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Reolysin: Phase III delayed

Oncolytics amended the double-blind, international Phase III REO 018 trial after blinded data for the combined Reolysin and chemotherapy control arms showed higher than expected median PFS and best response rate. Oncolytics said it expected a combined partial response rate of about 20%, but instead saw a >=30% rate. Oncolytics also said median evolving PFS for the combined arms was significantly higher in patients with distal metastatic disease compared to patients with a local head and neck tumor with or without metastatic disease (120 days...

Read the full 403 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >